Treatment of hepatitis C in solid organ transplantation

Area of Science:

• Hepatology
• Transplant Surgery
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a global health concern with significant morbidity and mortality.
• HCV impacts haemodialysis patients and kidney transplant recipients' long-term survival.
• HCV-infected patients with cirrhosis are generally not candidates for kidney or cardiac transplantation.

Purpose of the Study:

• To review the implications of Hepatitis C virus infection in solid organ transplant recipients.
• To provide recommendations for HCV treatment in kidney, cardiac, and liver transplant settings.
• To highlight the need for improved antiviral therapies in transplant patients.

Main Methods:

• Literature review of studies on Hepatitis C virus in transplant recipients.
• Analysis of treatment outcomes and survival rates in different transplant populations.
• Evaluation of current treatment guidelines and their limitations.

Main Results:

• HCV treatment is advised pre-kidney transplantation but contraindicated post-transplant due to rejection risk.
• HCV does not affect survival in cardiac transplant recipients; treatment is not recommended.
• HCV is a primary indication for liver transplantation, but re-infection is common, reducing survival.
• Interferon and ribavirin therapy for HCV in liver transplant recipients has significant adverse effects.

Conclusions:

• HCV management in transplant candidates and recipients requires careful consideration based on organ type.
• Current antiviral treatments for HCV in liver transplant patients are limited by side effects and efficacy.
• Development of novel, well-tolerated antiviral treatments is crucial for improving outcomes in HCV-infected transplant recipients.